Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of “Hold” by Analysts
Kadmon Holdings, Inc. (NYSE:KDMN) has received a consensus recommendation of “Hold” from the six analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $9.75.
A number of equities analysts recently commented on KDMN shares. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Friday, November 17th. Zacks Investment Research upgraded Kadmon from a “sell” rating to a “hold” rating in a report on Tuesday, November 21st. Finally, WBB Securities downgraded Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective on the stock. in a report on Monday, October 9th.
Large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC acquired a new position in Kadmon in the second quarter worth approximately $2,112,000. AE Wealth Management LLC grew its holdings in Kadmon by 33.6% during the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock valued at $1,083,000 after purchasing an additional 81,226 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in Kadmon during the third quarter valued at approximately $3,685,000. Vanguard Group Inc. grew its holdings in Kadmon by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after purchasing an additional 941,549 shares during the last quarter. Finally, Crestline Management LP acquired a new position in Kadmon during the third quarter valued at approximately $2,011,000. Hedge funds and other institutional investors own 51.90% of the company’s stock.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The company had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $5.69 million. During the same quarter in the prior year, the company earned ($4.24) EPS. The business’s revenue was down 60.0% compared to the same quarter last year. analysts expect that Kadmon will post -1.61 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of “Hold” by Analysts” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/kadmon-holdings-inc-kdmn-given-consensus-rating-of-hold-by-analysts/1773535.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.